BioSig Technologies (NASDAQ:BSGM) Price Target Raised to $10.00

BioSig Technologies (NASDAQ:BSGM) had its price objective increased by Ascendiant Capital Markets from $2.50 to $10.00 in a research note issued to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

BioSig Technologies Stock Performance

Shares of NASDAQ BSGM opened at $7.33 on Friday. The stock’s 50 day moving average price is $2.34 and its two-hundred day moving average price is $1.55. BioSig Technologies has a 52-week low of $0.20 and a 52-week high of $8.80.

BioSig Technologies (NASDAQ:BSGM) last announced its quarterly earnings data on Monday, May 19th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). On average, analysts anticipate that BioSig Technologies will post -0.88 EPS for the current year.

Institutional Investors Weigh In On BioSig Technologies

A number of institutional investors have recently modified their holdings of BSGM. Legacy Investment Solutions LLC bought a new position in BioSig Technologies in the fourth quarter worth about $5,369,000. Legacy Wealth Managment LLC ID raised its position in shares of BioSig Technologies by 72.5% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 6,216,508 shares of the company’s stock worth $3,737,000 after purchasing an additional 2,613,335 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of BioSig Technologies by 966.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 266,435 shares of the company’s stock worth $160,000 after purchasing an additional 241,447 shares during the last quarter. Millennium Management LLC acquired a new position in BioSig Technologies during the 4th quarter valued at approximately $228,000. Finally, Geode Capital Management LLC acquired a new stake in BioSig Technologies in the fourth quarter worth $143,000. Institutional investors own 7.16% of the company’s stock.

About BioSig Technologies

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.